OTC MiraLAX Must Contend With Prescription Competition – Court
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough failed to force firms offering Rx equivalents to MiraLAX laxative, which S-P markets as an OTC product, to stop using "prescription only" claims for their products, according to a federal court ruling
You may also be interested in...
S-P Brings New Laxative Class To OTC Market Under Braintree Licensing Deal
Schering-Plough will position Braintree Laboratories' MiraLAX laxative as an effective treatment for occasional constipation without "harsh" side effects linked to other OTC laxative products
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers